Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

Oct. 29, 1998

Japanese patent allowed for Maxamine technology

Oct. 22, 1998

Coulter announces positive investigational phase III results from Bexxar in NHL

Oct. 22, 1998

Endorex adds second site to phase II ImmTher trial

Oct. 16, 1998

Rituximab now available in Germany

Oct. 14, 1998

Antibody-based cancer product from AltaRex heading for phase I testing

Oct. 14, 1998

Coulter initiates expanded access program for Bexxar

Oct. 8, 1998

Patent issued for Neoprobe's RIGS/ACT anticancer technology

Oct. 7, 1998

Genentech's Herceptin given FDA approval

Sep. 28, 1998

Enzon's PEG-Intron A advances to phase III trials for malignant melanoma

Sep. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...